US OptionsDetailed Quotes
HUMA241220C2500
- 1.89
- -0.16-7.80%
15min DelayClose Dec 3 16:00 ET
2.05High1.83Low
2.05Open2.05Pre Close80 Volume1.45K Open Interest2.50Strike Price15.26KTurnover237.19%IV3.29%PremiumDec 20, 2024Expiry Date1.75Intrinsic Value100Multiplier16DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.9047Delta0.0791Gamma2.27Leverage Ratio-0.0112Theta0.0009Rho2.05Eff Leverage0.0015Vega
Humacyte Stock Discussion
🏄🏼♂️🏄🏼♂️🏄🏼♂️
🥱🥱🥱😴😴😴
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
Benzinga· 3 mins ago
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
what happened? the earnings suck but now the stock is rising
No comment yet